Skip to content
Peptigraph home

Thymosin Alpha-1 Dosage: Doses Studied, Units and Chart

What doses of Thymosin Alpha-1 have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureImmune modulatorUpdated
Doses studied
9 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
elimination half-life less than 3 hours; Tmax 1-2 hours
subcutaneous, in people · International journal of clinical pharmacology and therapeutics 1999, PMID 10027483

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of Thymosin Alpha-1 used in published studies
DoseFrequency and routeStudy typeSource
not stated in abstractevery 12 hours · subcutaneous · seven daysHuman RCTn = 1106BMJ 2025, PMID 39814420
3.2 mgtwice per day · injection · 7 daysHuman RCTn = 24Inflammation 2011, PMID 20549321
1.6 mg5 times weekly · SC · 24 weeksHuman RCTn = 25Hepatology international 2009, PMID 19669251
0.8 mg or 1.6 mgsix times weekly for two weeks, then twice weekly · not stated · 24 weeksHuman RCTn = 16Internal medicine 2003, PMID 14606705
900 microg/m2single dose and 5-day multiple dose · subcutaneousHuman RCTn = 9International journal of clinical pharmacology and therapeutics 1999, PMID 10027483
900 microg/m2 body surface areatwice weekly · subcutaneous (injection) · 6 monthsHuman RCTn = 33Hepatology 1996, PMID 8855175
900 micrograms/m2 body surface areatwice weekly · injection (route not stated) · 6 monthsHuman RCTn = 19Liver 1996, PMID 8873009
1.6 mgqd or q12 h · not stated · more than 5 daysHuman observationaln = 334International immunopharmacology 2020, PMID 32795897
1.6 mg (with IFN alpha 2a 3 mU)twice a week · s.c. · 52 weeksHuman uncontrolled trialn = 12Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2001, PMID 11529376

Before anyone considers it

  • Thymosin Alpha-1 is not FDA approved for any use.
  • Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Regimens in small randomised trials

A pilot trial randomised patients to 0.8 mg or 1.6 mg of thymosin alpha 1, given as an initial phase followed by twice-weekly doses for another 22 weeks.[6]

The low and high groups did not differ significantly (p = 0.608).[6]

A phase II liver-cancer trial used 1.6 mg subcutaneously, 5 times weekly, for 24 weeks alongside chemoembolization.[5]

In severe acute pancreatitis the regimen was 3.2 mg twice per day for 7 days.[4]

Pharmacokinetics

A 9-volunteer crossover compared three formulations at 900 microg/m2 subcutaneously, reporting a short elimination half-life of less than 3 hours.[7]

Status

Drugs@FDA returned no thymalfasin match, so no US label sets a regimen.[12]

Common questions

Is Thymosin Alpha-1 FDA approved?

No. Thymosin Alpha-1 is not FDA approved for any use.

What is the thymosin alpha 1 dosing in studies?

One trial design is 1.6 mg subcutaneously 5 times weekly for 24 weeks, alongside chemoembolization in liver cancer.[5]

Is there a thymosin alpha 1 dosage chart or protocol?

The cleanest comparison in the cached set is the hepatitis B pilot, which randomised 0.8 mg against 1.6 mg.[6]

More on Thymosin Alpha-1

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
  4. 4Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.Inflammation · 2011PMID 20549321Accessed 2 Oct 2026
  5. 5A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.Hepatology international · 2009PMID 19669251Accessed 2 Oct 2026
  6. 6A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.Internal medicine (Tokyo, Japan) · 2003PMID 14606705Accessed 2 Oct 2026
  7. 7Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.International journal of clinical pharmacology and therapeutics · 1999PMID 10027483Accessed 2 Oct 2026
  8. 8Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.International immunopharmacology · 2020PMID 32795897Accessed 2 Oct 2026
  9. 9A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.Hepatology (Baltimore, Md.) · 1996PMID 8855175Accessed 11 Oct 2026
  10. 10A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.Liver · 1996PMID 8873009Accessed 11 Oct 2026
  11. 11The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 2001PMID 11529376Accessed 11 Oct 2026
  12. 12Drugs@FDA (openFDA) search: active ingredient "thymalfasin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.